1189881-87-5
1189881-87-5
Chemical Structure
Bisoprolol-d5
- CAS No.: 1189881-87-5
- Formula:C18H26D5NO4
- Molecular Weight:330.47
IUPAC Name: 1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-(isopropylamino)propan-1,1,2,3,3-d5-2-ol
InChIKey: VHYCDWMUTMEGQY-FFNOJTKMSA-N
SMILES: CC(C)NC([2H])([2H])C(O)([2H])C([2H])([2H])OC1=CC=C(C=C1)COCCOC(C)C
Biological Activity: Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bisoprolol-d5 | 92.74% | Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bisoprolol-d7 hemifumarate | Bisoprolol-d7 (hemifumarate) is the deuterium labeled Bisoprolol hemifumarate. Bisoprolol hemifumarate is a selective type β1 adrenergic receptor blocker. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bisoprolol hemifumarate | 99.84% | Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Jillian G Baker, et al. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005 Feb;144(3):317-22. [Content Brief]
